Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Baycol

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Company is voluntarily withdrawing cerivastatin from the U.S. due to reports of 31 deaths from severe rhabdomyolysis, FDA says Aug. 8. The fatalities have been reported most frequently, FDA said, when Baycol has been "used at higher doses, when used in elderly patients, and particularly, when used in combination with gemfibrozil (Pfizer's Lopid and generics)." Twelve of the fatalities involved concomitant gemfibrozil use. Bayer says it has no plans to reintroduce the statin in the U.S. and will probably stop ongoing diabetes and longer-term cardiovascular trials

You may also be interested in...



Alembic Aims To Build On Booming US Business

With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.

Dermocosmetics Push Yields Results For Switzerland's Galenica

Launching skin-care products that blend "natural medicinal plants from the Swiss pharmacopoeia with the best Swiss skin science" helped to drive up Galenica's OTC sales in 2019 at a double-digit rate.

Commission Provides Latest Notified Body Figures: How Does Update Help Industry?

Updated medtech notified body figures from the European Commission always make headline news. But industry needs to see real appointments now, not a list of tricky-to-understand numbers.

Topics

UsernamePublicRestriction

Register

PS001562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel